Literature DB >> 15851227

Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing.

Michael J Ackerman1, Igor Splawski, Jonathan C Makielski, David J Tester, Melissa L Will, Katherine W Timothy, Mark T Keating, Gregg Jones, Monica Chadha, Christopher R Burrow, J Claiborne Stephens, Chuanbo Xu, Richard Judson, Mark E Curran.   

Abstract

OBJECTIVES: The purpose of this study was to determine the prevalence and spectrum of nonsynonymous polymorphisms (amino acid variants) in the cardiac sodium channel among healthy subjects.
BACKGROUND: Pathogenic mutations in the cardiac sodium channel gene, SCN5A, cause approximately 15 to 20% of Brugada syndrome (BrS1), 5 to 10% of long QT syndrome (LQT3), and 2 to 5% of sudden infant death syndrome.
METHODS: Using single-stranded conformation polymorphism, denaturing high-performance liquid chromatography, and/or direct DNA sequencing, mutational analysis of the protein-encoding exons of SCN5A was performed on 829 unrelated, anonymous healthy subjects: 319 black, 295 white, 112 Asian, and 103 Hispanic.
RESULTS: In addition to the four known common polymorphisms (R34C, H558R, S1103Y, and R1193Q), four relatively ethnic-specific polymorphisms were identified: R481W, S524Y, P1090L, and V1951L. Overall, 39 distinct missense variants (28 novel) were elucidated. Nineteen variants (49%) were found only in the black cohort. Only seven variants (18%) localized to transmembrane-spanning domains. Four variants (F1293S, R1512W, and V1951L cited previously as BrS1-causing mutations and S1787N previously published as a possible LQT3-causing mutation) were identified in this healthy cohort.
CONCLUSIONS: This study provides the first comprehensive determination of the prevalence and spectrum of cardiac sodium channel variants in healthy subjects from four distinct ethnic groups. This compendium of SCN5A variants is critical for proper interpretation of SCN5A genetic testing and provides an essential hit list of targets for future functional studies to determine whether or not any of these variants mediate genetic susceptibility for arrhythmias in the setting of either drugs or disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15851227     DOI: 10.1016/j.hrthm.2004.07.013

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  91 in total

1.  Coexisting mutations/polymorphisms of the long QT syndrome genes in patients with repaired Tetralogy of Fallot are associated with the risks of life-threatening events.

Authors:  Shuenn-Nan Chiu; Mei-Hwan Wu; Ming-Jai Su; Jou-Kou Wang; Ming-Tai Lin; Chien-Chih Chang; Hui-Wen Hsu; Ching-Tsuen Shen; Olivier Thériault; Mohamed Chahine
Journal:  Hum Genet       Date:  2012-03-11       Impact factor: 4.132

2.  Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing.

Authors:  David J Tester; Argelia Medeiros-Domingo; Melissa L Will; Carla M Haglund; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

Review 3.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

4.  Racial differences in sudden cardiac death.

Authors:  Erin A Fender; Charles A Henrikson; Larisa Tereshchenko
Journal:  J Electrocardiol       Date:  2014-08-01       Impact factor: 1.438

Review 5.  Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.

Authors:  Jae-Gook Shin; Won-Ku Kang; Ji-Hong Shon; Million Arefayene; Young-Ran Yoon; Kyung-Ah Kim; Doo-Il Kim; Dong-Soo Kim; Kwang-Hyun Cho; Raymond L Woosley; David A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

7.  Enhanced Classification of Brugada Syndrome-Associated and Long-QT Syndrome-Associated Genetic Variants in the SCN5A-Encoded Na(v)1.5 Cardiac Sodium Channel.

Authors:  Jamie D Kapplinger; John R Giudicessi; Dan Ye; David J Tester; Thomas E Callis; Carmen R Valdivia; Jonathan C Makielski; Arthur A Wilde; Michael J Ackerman
Journal:  Circ Cardiovasc Genet       Date:  2015-04-22

8.  Mechanosensitivity of Nav1.5, a voltage-sensitive sodium channel.

Authors:  Arthur Beyder; James L Rae; Cheryl Bernard; Peter R Strege; Frederick Sachs; Gianrico Farrugia
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

9.  Genetics can contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification.

Authors:  Elena Sommariva; Carlo Pappone; Filippo Martinelli Boneschi; Chiara Di Resta; Maria Rosaria Carbone; Erika Salvi; Pasquale Vergara; Simone Sala; Daniele Cusi; Maurizio Ferrari; Sara Benedetti
Journal:  Eur J Hum Genet       Date:  2013-01-16       Impact factor: 4.246

10.  Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing.

Authors:  Lia Crotti; Cherisse A Marcou; David J Tester; Silvia Castelletti; John R Giudicessi; Margherita Torchio; Argelia Medeiros-Domingo; Savastano Simone; Melissa L Will; Federica Dagradi; Peter J Schwartz; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2012-07-25       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.